MindBio Therapeutics Corp.
MBIO
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.71% | -57.70% | -94.82% | 0.29% | 68.27% |
| Depreciation & Amortization | 83.49% | -- | -21.41% | 63.58% | 98.11% |
| Other Operating Expenses | -- | -44.20% | -- | -- | -- |
| Total Operating Expenses | 20.07% | -53.43% | -97.89% | 6.88% | 75.71% |
| Operating Income | -910.84% | 53.43% | 75.02% | 178.00% | 126.02% |
| Income Before Tax | -857.85% | 75.41% | 92.33% | 124.57% | 89.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -857.85% | 75.41% | 92.33% | 124.57% | 89.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -300.00% | -- | -- | -- |
| Net Income | -847.13% | 75.04% | 92.33% | 124.57% | 89.43% |
| EBIT | -910.84% | 53.43% | 75.02% | 178.00% | 126.02% |
| EBITDA | -319.75% | -- | -- | 206.31% | 200.42% |
| EPS Basic | -500.00% | 81.82% | 80.00% | 105.71% | 96.84% |
| Normalized Basic EPS | -450.00% | 85.71% | 77.78% | 104.55% | 96.67% |
| EPS Diluted | -500.00% | 81.82% | 80.00% | 105.71% | 96.84% |
| Normalized Diluted EPS | -450.00% | 85.71% | 77.78% | 104.55% | 96.67% |
| Average Basic Shares Outstanding | 34.90% | 21.66% | -61.06% | 347.92% | 287.22% |
| Average Diluted Shares Outstanding | 34.90% | 21.66% | -61.06% | 347.92% | 287.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
